Incredible Hulk

Diagnosis
Lung adenocarcinoma

Accession No.
TL-22-AZDK9PBT

IHC

Date of Birth
01/01/1990

Sex
Male

Physician
Test Physician

Institution
Test Institution 123456789

TEMPUS | IHC

Analysis performed using
VENTANA PD-L1 SP263 clone.

Tumor specimen:
Lung, left
Test Institution Pathology
Laboratory S22-123456, A2
Collected 02/06/2022
Received 02/09/2022
Tumor Percentage: 70%

PD-L1 EXPRESSION

Positive

Tumor cell staining (TC)

70%



H&E



PD-L1

FDA approved companion diagnostic interpretation cutoffs are based on tumor subtype. Approved indications are as follows:

Tumor Cell Staining (TC) Expression Levels

Tumor indication	Expression level
Non-Small Cell Lung Cancer	≥ 1%

Interpretation Guidelines

The Tempus PD-L1 SP263 IHC test is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP263 intended for use in the assessment of the PD-L1 protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tissues using the DISCOVERY ULTRA system. Determination of programmed death-ligand 1 (PD-L1) status is indication-specific, and evaluation is based on the percentage of PD-L1 expressing tumor cells (% TC) of any intensity. Scoring interpretation is not provided in tumors for which no scoring system has been published. See clinical practice guidelines for specific clinical circumstances guiding PD-L1 testing. Results (positive/negative) are determined based on available clinical information provided at the time of test interpretation. Test results should be interpreted in the context of clinical findings by a treating physician.

Tempus Disclaimer

This test was developed and its performance characteristics determined by Tempus Labs, Inc. It has not been cleared or approved by the US Food and Drug Administration. The laboratory is CLIA certified to perform high-complexity testing. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing. All controls were reviewed and show appropriate positive or negative reactivity. This assay has not been validated on decalcified tissue or cytology specimens; results from these tissue types should be interpreted with caution. In reports containing photographic images, those images should be considered representative and should not be used for diagnostic purposes. These test results and Information contained within the report are current as of the report date. Any decisions related to patient care and treatment choices should be based on the independent judgment of the treating physician and should take into account all information related to the patient, including without limitation, the patient and family history, direct physical examination and other tests. Tempus is not liable for medical judgment with regards to diagnosis, prognosis or treatment in connection with the test results.

Dates and times are represented in the coordinated universal time zone (UTC) unless otherwise specified. However, dates that are provided to Tempus without a timestamp (e.g., sample collection date) are listed as provided.